Extraction generator of 223Ra for nuclear medicine

Shishkin, D. N.; Krupitskii, S. V.; Kuznetsov, S. A.

doi:10.1134/s1066362211040126

Cited by 13 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Production of alpha-particle emitters includes, in general, practically all methods for preparation of radionuclide sources—irradiation with charged particles in accelerators, neutron irradiation in a nuclear reactor, separation from long-lived natural radionuclides and various combinations thereof [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ]. The great advantage of nuclides decaying in a series over single alpha particle emitters is not only in the higher energy deposition in target tissue but, thanks to the good nuclear characteristics, also the possibility of construction of a radionuclide generator.…”

Section: Production Of Alpha Emittersmentioning

confidence: 99%

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

2018

View full text Add to dashboard Cite

This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.

show abstract

Section: Production Of Alpha Emittersmentioning

confidence: 99%

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

2018

View full text Add to dashboard Cite

show abstract

“…Despite promising results, the main impediment to the widespread use of alfa emitters in targeted therapy is the high cost of their production and low availability, which is currently sufficient to conduct only preclinical studies and a limited number of clinical trials [9,10]. The exception is 223 Ra radionuclide, which can be produced in large amounts and relatively inexpensively [11]. 223 Ra emits particles with a linear energy transfer (LET) of~28 MeV over a range of ≤100 mcm [12].…”

Section: Introductionmentioning

confidence: 99%

Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution

Lankoff

Czerwińska

Walczak

et al. 2021

IJMS

View full text Add to dashboard Cite

Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the life of mCRPC patients is PSMA-based targeted radioimmunotherapy. In this paper, we extended our in vitro study of 223Ra-labeled and PSMA-targeted NaA nanozeolites [223RaA-silane-PEG-D2B] by undertaking comprehensive preclinical in vitro and in vivo research. The toxicity of the new compound was evaluated in LNCaP C4-2, DU-145, RWPE-1 and HPrEC prostate cells and in BALB/c mice. The tissue distribution of 133Ba- and 223Ra-labeled conjugates was studied at different time points after injection in BALB/c and LNCaP C4-2 tumor-bearing BALB/c Nude mice. No obvious symptoms of antibody-free and antibody-functionalized nanocarriers cytotoxicity and immunotoxicity was found, while exposure to 223Ra-labeled conjugates resulted in bone marrow fibrosis, decreased the number of WBC and platelets and elevated serum concentrations of ALT and AST enzymes. Biodistribution studies revealed high accumulation of 223Ra-labeled conjugates in the liver, lungs, spleen and bone tissue. Nontargeted and PSMA-targeted radioconjugates exhibited a similar, marginal uptake in tumour lesions. In conclusion, despite the fact that NaA nanozeolites are safe carriers, the intravenous administration of NaA nanozeolite-based radioconjugates is dubious due to its high accumulation in the lungs, liver, spleen and bones.

show abstract

“…223 Ra with a solution of chlorinated cobalt dicarbollide and polyethylene glycol in a polar diluent from a solution of a mineral acid has also been reported. 110 In another interesting study, a solvent extraction 172 Hf/ 172 Lu generator system based on the extraction of 172 Lu with a solution of HDEHP in 9 M HCl was reported. 111 While the classical liquid-liquid extraction (LLE), in combination with chelation chemistry, is an attractive method for the separation of radionuclides, the shortcomings of this technique as discussed above limit its applicability to date.…”

Section: Solvent Extractionmentioning

confidence: 99%

Pivotal role of separation chemistry in the development of radionuclide generators to meet clinical demands

Dash

Chakravarty

2014

RSC Adv.

View full text Add to dashboard Cite

Extraction generator of 223Ra for nuclear medicine

Cited by 13 publications

References 4 publications

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution

Pivotal role of separation chemistry in the development of radionuclide generators to meet clinical demands

Contact Info

Product

Resources

About